Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

ClinicalTrials.gov ID: NCT01691755

Public ClinicalTrials.gov record NCT01691755. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared With Placebo in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Study identification

NCT ID
NCT01691755
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
196 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • aleglitazar Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2012
Primary completion
Aug 31, 2013
Completion
Aug 31, 2013
Last update posted
Aug 10, 2016

2012 – 2013

United States locations

U.S. sites
23
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Not listed Chino California 91710
Not listed Los Angeles California 90057
Not listed Santa Ana California 92701
Not listed Thousand Oaks California 91360
Not listed Upland California 91786
Not listed West Hills California 91307
Not listed Boynton Beach Florida 33472
Not listed Cooper City Florida 33024
Not listed Coral Gables Florida 33134
Not listed Jacksonville Florida 32216
Not listed Kissimmee Florida 34741
Not listed Atlanta Georgia 30338
Not listed Chicago Illinois 60607
Not listed Avon Indiana 46123
Not listed City of Saint Peters Missouri 63376
Not listed Greensboro North Carolina 27408
Not listed Portland Oregon 97239
Not listed Altoona Pennsylvania 16602
Not listed Scranton Pennsylvania 18510
Not listed Tipton Pennsylvania 16684
Not listed Greer South Carolina 29651
Not listed Knoxville Tennessee 37919
Not listed Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01691755, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01691755 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →